Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that, yesterday, Dr Mike Sinclair purchased 200,000 Ordinary Shares of 25 pence in the Company at an average price of 30.44 pence per Ordinary Share.
Following this transaction, Dr Sinclair now holds 4,928,229 Ordinary Shares, representing 6.65% of the issued share capital of 74,156,188 Ordinary Shares.
|
Advanced Oncotherapy Plc |
|
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CEO |
|
|
Stockdale Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Stifel Nicolaus Europe (Joint Broker) |
|
|
Jonathan Senior / Ben Maddison |
Tel: +44 20 7710 7600 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |